shelf(0)

No. 008 · GH & Growth · Growth Hormone

Ipamorelin

NNC 26-0161Ipamorelin acetate

A Tier A · Controlled human trials how tiers work →
  • Not FDA approved
  • WADA ✗ S2
Compare Cite
Fingerprint no sequence
Ipamorelin (no defined sequence)

No sequence on file. We only draw fingerprints from published sequences — this ring motif is a placeholder, never a guessed sequence.

01

Evidence

  1. D In vitro
  2. C Animal
  3. B Human pilot
  4. A RCT
  5. S Approved

TIER A — At least one published randomized controlled trial in humans.

Randomized, placebo-controlled phase 2 trials in postoperative ileus were completed (no benefit shown); not approved.

Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.

02

At a glance

Discovered
1998 Described by Novo Nordisk as a selective GH secretagogue.
Routes studied
Subcutaneous, Intramuscular Routes used in published research
FDA
Not approved
WADA
Prohibited · S2 Peptide hormones, growth factors, related substances and mimetics
03

Overview

A selective growth hormone secretagogue that stimulates the pituitary gland with minimal impact on cortisol or prolactin. Considered one of the mildest and most targeted GH-releasing peptides.

Research status Phase II clinical data available; well-characterized safety and selectivity profile

04

Mechanism

Ipamorelin is a pentapeptide ghrelin receptor (GHS-R1a) agonist that stimulates growth hormone release from the anterior pituitary in a dose-dependent manner. Unlike other GHRPs, it has high selectivity for GH release without significantly elevating ACTH, cortisol, or prolactin, making it the cleanest GHRP available.

05

Effects reported in research

Reported outcomes, not promises. Some come from controlled human trials; others may be from smaller or preclinical studies — check the studies below.

  • Increased growth hormone release
  • Improved sleep quality
  • Enhanced fat metabolism
  • Strengthened bone mineral density
06

Safety & unknowns

Well-tolerated in Phase II clinical trials. Common side effects include transient headache, flushing, and mild water retention. Does not significantly raise cortisol or prolactin. Not FDA-approved. Banned by WADA.

Unknowns. Trial safety data apply to the populations, formulations and conditions studied.

Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.

07

Studies [0]

No studies cited for this entry yet.

09

Status sources

Sources behind the tier, regulatory status, sequence and dates on this page.

10

Cite this entry

$ cite --format=apa

peptidemeta. (2026). Ipamorelin. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/ipamorelin/

$ cite --format=bibtex 
@misc{peptidemeta-ipamorelin,
  title = {Ipamorelin},
  author = {{peptidemeta}},
  year = {2026},
  howpublished = {\url{https://peptidemeta.com/p/ipamorelin/}},
  note = {Accessed 2026-11-08}
}

Accessed date reflects when you opened this page. Cite primary studies for scientific claims.

esc
↑↓ navigate ↵ open